Skip to content
Peptide Atlas
All peptides

TB-500

Tier 2 · Preclinical
Also known as TB500 · Thymosin Beta-4 fragment · TB4

Tier-1 human evidence is present, but with a critical caveat repeated across sources: nearly all of it was generated with pharmaceutical-grade full-length recombinant thymosin beta-4, not the TB-500 fragment sold in unregulated markets. Tier-1 human RCT/observational sources include the MOTIF cardiac trial, dry eye Phase 2b, Phase 3 ARISE safety trials (src-3), neurotrophic keratopathy and cardiac trials (src-2), and an HFpEF plasma-biomarker cohort (src-29). Multiple sources (src-4, src-5, src-7, src-8, src-13, src-15) emphasize there are no completed human efficacy trials of the TB-500 fragment specifically; src-1's scoping review found direct TB-500 human evidence limited to a single included study. Lower-tier animal, in vitro, expert-opinion and community claims dominate the remainder.

Half-life
~4 h
Routes
Subcutaneous · Intramuscular · Intravenous · Topical (ophthalmic/dermal in trials) · Sublingual · Oral
Goals
Injury recovery / tissue repair · Wound healing · Anti-inflammatory support · Cardiovascular repair (research) · Joint / musculoskeletal recovery
Cost / mg
$22

How it works

According to the source set, TB-500 is described as a lab-made version of thymosin beta-4, a small peptide that occurs naturally in nearly every human cell. Sources report its core action is grabbing hold of the cell's building-block protein actin, which lets cells move, migrate to injury sites and reorganize — processes tied to wound healing. Across animal and lab studies, sources describe it promoting new blood-vessel growth, calming inflammation and helping tissue repair. Two big cautions run through the sources: sources disagree on whether TB-500 is a short 7-amino-acid fragment or the full 43-amino-acid protein, and almost all human trial data actually used the full-length pharmaceutical protein rather than the fragment vendors sell — so whether the injected fragment itself works is genuinely disputed.

Overview

What sources say TB-500 is

A tier-2 vendor source (src-2) and several others describe TB-500 as a synthetic form related to Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide encoded by the TMSB4X gene on the X chromosome, ubiquitously expressed in nearly all tissues except erythrocytes, with highest concentrations in platelets and wound fluid. A tier-1 review (src-3) notes Tβ4 is one of the most abundant intracellular peptides in mammalian cells, present at ~0.5 mM in platelets.

The identity of TB-500 is itself contested across the sources. Many sources (src-3, src-4, src-5, src-7, src-8, src-11, src-13) describe TB-500 as a short synthetic fragment — variously a 7-amino-acid acetylated heptapeptide (Ac-LKKTETQ, ~843-889 Da) or 17-residue peptide (~1.9 kDa, src-10) corresponding to residues 17-23 of Tβ4. Other sources (src-2, src-9, src-12, src-30) describe TB-500 as the full 43-amino-acid peptide (~4,963 Da). A tier-4 source (src-5) stresses that TB-500 is NOT identical to full-length Tβ4 — different molecular weight, structure, pharmacokinetics and evidence base.

Reported mechanisms

Across tier-1 through tier-4 sources, the described core mechanism is G-actin sequestration regulating cytoskeletal dynamics and cell migration (src-6, src-18, src-2). Preclinical/expert sources additionally report angiogenesis via VEGF upregulation (src-4, src-9, src-14), anti-inflammatory signaling through reduced TNF-α, IL-1β and IL-6 and NF-κB suppression (src-9, src-4), and repair signaling via Akt/PI3K, ERK1/2, p38 MAPK, mTOR, TGF-β, AMPK, HGF (src-9, src-68) and Wnt/β-catenin (src-14). A tier-1 review (src-3) reports that in preclinical models TB-500 retains the G-actin sequestration activity of full-length Tβ4 and produces equivalent cell migration and anti-inflammatory effects — though src-6 and src-7 explicitly note this assumed equivalence has not been rigorously validated, and src-11 reports a March 2024 study in which TB-500 (Ac-LKKTETQ) did not enhance wound healing whereas its metabolite Ac-LKKTE did.

The human evidence base — and its central caveat

Multiple sources (src-4, src-5, src-7, src-8, src-13, src-15) emphasize that essentially all published human clinical trial data used pharmaceutical-grade full-length recombinant Tβ4, not the TB-500 fragment:

  • Ophthalmic: src-2 reports a Phase 3 RCT for neurotrophic keratopathy showing 60% healing vs 12.5% placebo (p=0.036 at day 43), but the European confirmatory Phase 3 (SEER-3) failed its primary endpoint; a US SEER-2 trial (N=70) was recruiting. src-3 reports dry eye Phase 2b trials (RGN-259) showed statistically significant corneal-staining improvements, and that the Phase 3 ARISE trials provided the largest human Tβ4 safety dataset. src-15 notes no Tβ4 studies have gone past Phase 2 for FDA approval — an apparent tension in how the landscape is characterized.
  • Cardiac: src-3 reports the MOTIF trial showed statistically significant improvements in myocardial viability by cardiac MRI post-MI with a favorable safety profile; src-2 reports a Phase 2 cardiac trial (N=90, NL005) improved cardiac function post-MI.
  • Wound healing: src-11 reports a European double-blind placebo-controlled study (n=73) in which 0.03% topical TB-500 gave complete healing in ~25% of patients within 3 months and ~1-month acceleration in some, but overall healing rates were not conclusively superior to control — a qualifier vendor sources describing robust efficacy omit.

A tier-3 scoping review (src-1) identified 1772 records and included 80 studies, but reports the evidence base is weighted toward mixed/in vitro designs, remains largely preclinical, and that direct TB-500 human evidence was limited to a single included study. A tier-4 source (src-5) states there are 0 human studies of the TB-500 fragment versus 6 animal and 3 in vitro studies, describing it as one of the most widely used peptides in the self-experimentation community while being one of the least tested in humans.

Preclinical and single-study signals

Animal/in-vitro sources report accelerated wound re-epithelialization and contraction (src-11, src-50, src-45), cardiac cell migration/survival and improved function after coronary ligation (src-21), and support for muscle and tendon recovery in rodents (src-49). Single, uncorroborated studies within the set report: neuroprotective and cognitive benefits in 5×FAD Alzheimer's mice (src-25), a fetal growth-promoter effect in mice (src-27), corneal repair via a TB500 hydrogel (src-28), tympanic-membrane cell effects in vitro (src-30), and elevated plasma TB4 in HFpEF (especially women, src-29). A tier-2 human observational report (src-16) found that of 4 patients given BPC157+TB4 intra-articular injections, 3/4 (75%) improved in knee pain.

Regulatory and sport status

Sources agree TB-500 is not FDA-approved (src-4, src-8, src-13, src-14) and is prohibited under WADA — described as S0 unapproved substances (src-24 context/src-4) and Section S2 growth factors (src-7, src-8, src-11, src-13). src-4 notes orphan drug designation for epidermolysis bullosa. Reported 503A reclassification dates differ: src-13 cites a February 2026 reclassification to 503A Category 2, while src-7 and src-8 state TB-500 was removed from 503A Category 2 in April 2026 (src-8: April 15, 2026); all agree a PCAC review was scheduled for July 23, 2026, with src-7 reporting the FDA proposed NOT to add TB-500 to the 503A bulks list.

What the research shows

306 findings extracted from the 30 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 12 human trial findings, 12 human study findings, 23 animal findings, 5 in vitro findings, 23 expert opinion findings and 2 theoretical findings.

  • human trialThe MOTIF trial showed statistically significant improvements in myocardial viability by cardiac MRI in post-MI subjects, with a favorable safety profile at all dose levels tested1

  • human trialDry eye Phase 2b trials showed statistically significant improvements in corneal staining scores with topical Thymosin Beta-4 (RGN-259)1

  • human trialPhase 3 ARISE trials provided the largest human Thymosin Beta-4 safety dataset1

  • human trialThymosin Beta-4 has published Phase 2 human clinical trial data from RegeneRx Biopharmaceuticals in dry eye disease, cardiac repair (MOTIF trial), and peripheral artery disease1

  • human trialPhase 3 RCT for neurotrophic keratopathy showed 60% healing vs 12.5% placebo (p=0.036 at day 43)3

  • human trialEuropean confirmatory Phase 3 trial (SEER-3) for neurotrophic keratopathy failed its primary endpoint3

  • human trialPhase 2 cardiac trial (N=90) completed by Beijing Northland Biotech (NL005) showing improved cardiac function post-MI3

  • human trialPhase 2 RCT trials conducted for dry eye disease3

Show the remaining 69

  • human trialPilot study in STEMI patients (Phase 2 IV, post-PCI)3

  • human trialAll published clinical trial data including the Phase I safety study by Ruff et al. (2010), the RGN-259 ophthalmic trials, and the SEER trials for neurotrophic keratopathy used pharmaceutical-grade, full-length recombinant thymosin beta-4 (all 43 amino acids), NOT the TB-500 fragment sold in unregulated markets4

  • human trialThe parent molecule has human clinical trial data for ophthalmic and cardiac applications25

  • human trialThymosin beta-4 is the full 43-amino-acid molecule that has been studied in human clinical trials25

  • human studyPlasma TB4 was elevated in HFpEF patients compared with controls (1401 [720-2379] ng/mL versus 985 [421-1723] ng/mL, p<0.001)2

  • human studyPlasma TB4 was not significantly elevated in HFrEF patients compared with controls (1106 [556-1955] ng/mL, p=0.642)2

  • human studyWomen with HFpEF had significantly elevated TB4 compared to controls (1623 [1040-2625] ng/mL versus 942 [386-1891] ng/mL, p<0.001)2

  • human studyMen with HFpEF did not have significantly elevated TB4 compared to controls (1238.5 [586-1967] ng/mL versus 1004 [451-1538] ng/mL, p=1.0)2

  • human studyHazard ratio to all-cause mortality is significantly higher in women with elevated TB4 (1.668, p=0.036), but not in men (0.791, p=0.456) with HF2

  • human studyVenous stasis ulcers trial (small European study)3

  • human studyOf 4 patients who received a combination of BPC157 and TB4 intra-articular injections, 75% showed significant improvement in knee pain, but 25% had no relief10

  • human studyOf 12 patients who received only BPC157 as an intra-articular injection, 11 of 12 patients (91.6%) had significant improvement in knee pain, whereas 1 patient (8.3%) had no improvement10

  • human studyOverall, 14 of 16 patients (87.5%) had relief of knee pain when BPC157 or a combination of BPC157 and TB4 was used10

  • human studyIn a European double-blind, placebo-controlled study (n=73), 0.03% topical TB-500 led to complete healing in approximately 25% of patients within 3 months, typically in small to moderate venous stasis ulcers16

  • human studyIn pressure and stasis ulcers, TB-500 accelerated healing by nearly one month in some patients, but overall healing rates were not conclusively superior to control16

  • human studyThymosin Alpha-1 can increase T-cell production by up to 40% in immunocompromised patients21

  • animalTB500 ameliorated cognitive impairments in 5×FAD mice as evidenced by improved performance in Morris water maze6

  • animalTB500 improved performance in novel object recognition tests in 5×FAD mice6

  • animalTB500 reduced glial activation in 5×FAD mice6

  • animalTB500 reduced neuronal apoptosis in 5×FAD mice6

  • animalTB500 restored axonal density in the perirhinal cortex of 5×FAD mice6

  • animalTB500 attenuated β-amyloid (Aβ) plaque-associated dystrophic neurites in 5×FAD mice, though hippocampal Aβ burden remained unchanged6

  • animalIn an alkali burn model, the hydrogel significantly accelerated epithelial regeneration, reduced inflammation, and improved corneal barrier function7

  • animalTB4 enhances myocyte survival and improves cardiac function after coronary artery ligation9

  • animalMothers treated with TB4 showed higher cranio-caudal length in newborns compared to control newborns11

  • animalMaternal TB4 treatment was associated with more advanced development of lungs, heart, kidney, cerebral cortex and notochord at histology11

  • animalAnimal wound-healing data using both full-length Tβ4 and short actin-binding fragments exists15

  • animalA 2003 study showed that both full-length Tβ4 and a synthetic peptide containing only its actin-binding domain accelerated dermal wound healing in diabetic and aged mouse models15

  • animalTβ4 has demonstrated accelerated wound healing, increased angiogenesis, enhanced cardiac repair following ischemic injury, as well as support for skeletal muscle and tendon recovery in rodent models16

  • animalA 2003 study determined that application of Tβ4 in mice accelerated re-epithelialization and wound contraction when compared to saline controls16

  • animalResearch published in March 2024 reported that TB-500 (Ac-LKKTETQ) did not enhance wound healing activity, whereas its metabolite, Ac-LKKTE, did16

  • animalThere is evidence on animals that TB-500 might help heart muscles or other tissues repair more quickly18

  • animalTB-500 demonstrates ability to promote wound healing, reduce inflammation, and enhance tissue repair across multiple organ systems in preclinical models20

  • animalPreclinical studies demonstrate TB-500's efficacy in accelerated closure rates in cutaneous wounds with improved healing timeline20

  • animalTB-500 demonstrates enhanced re-epithelialization and granulation tissue formation in wound healing20

  • animalResearch indicates potential benefits of TB-500 in diabetic ulcer healing acceleration and prevention of complications20

  • animalTB-500 demonstrates significant tissue repair acceleration in preclinical models21

  • animalUnapproved peptides like TB-500 demonstrate favorable tissue repair outcomes in animal models26

  • animalIn animal studies, the parent protein speeds up wound healing, grows new blood vessels, and reduces swelling29

  • in vitroTB500 significantly attenuated neurite atrophy in Aβ25-35-treated HT22 cells6

  • in vitroTB500 restored cell viability in Aβ25-35-treated HT22 cells and primary cortical neurons6

  • in vitroNap-YpYY-TB500 hydrogel promoted human corneal epithelial cell (HCEC) migration, proliferation, and tight junction recovery in vitro7

  • in vitroTB4 induces tumor metastasis and paclitaxel resistance13

  • in vitroSoluble TB4 peptides produced in cancer cells could be an obstacle to treat tumors with paclitaxel13

  • expert opinionMost published clinical evidence uses pharmaceutical-grade recombinant Tβ4 (e.g., RegeneRx's RGN-259 for eyes, NL005 for cardiac)3

  • expert opinionTB-4 and its derivative TB-500 human orthopaedic data are lacking5

  • expert opinionTB-500 is a synthetic 17-amino acid fragment of thymosin beta-4 with no completed human efficacy trials as of April 202615

  • expert opinionFull-length thymosin beta-4 has progressed through clinical trials for an ophthalmic indication, but TB-500 specifically has not15

  • expert opinionNo completed human efficacy trials for TB-500 (the 17-amino acid fragment) have been published as of April 202615

  • expert opinionThere are no controlled human clinical trials for TB-500, and clinical research for thymosin beta-4 is limited and indication-specific16

  • expert opinionResearch shows TB-500 promotes angiogenesis, reduces inflammation, improves tissue flexibility, and accelerates recovery from musculoskeletal injuries17

  • expert opinionDemonstrated acceleration of wound healing and soft tissue repair in research17

  • expert opinionResearch shows beneficial effects on intestinal lining and GI function17

  • expert opinionAssociated with reduced joint inflammation and improved mobility17

  • expert opinionMay support faster recovery from muscle strains and exercise stress17

  • expert opinionThere are no studies of thymosin beta-4 that have gone past Phase 2 for FDA approval18

  • expert opinionStudies conducted on humans with thymosin beta-4 have only been for external use such as dry eye or skin conditions18

  • expert opinionAnimal evidence for TB-500 has not been shown in humans18

  • expert opinionThese dosing ranges are drawn largely from animal research and community practice — not a validated human prescription, because no controlled human trial has ever established a TB-500 dose22

  • expert opinionEssentially the entire published efficacy literature was generated with the full-length Tβ4 protein, not the fragment22

  • expert opinionWhen you search the peer-reviewed literature for TB-500 specifically, you find almost nothing: no completed human clinical trials of the fragment for any indication22

  • expert opinionThe human data that exists — a Phase 1 safety program, Phase 2 dermal wound-healing trials, and Phase 3 ophthalmic trials — was all conducted on full-length thymosin beta-4, not on the LKKTETQ fragment22

  • expert opinionMost human research used full 43-amino-acid thymosin beta-4, not the 7-amino-acid TB-500 fragment23

  • expert opinionHuman evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings24

  • expert opinionDirect TB-500 evidence was limited to a single included study24

  • expert opinionThe mapped literature supports the popular interest in several repair-related pathways but remains unevenly distributed and largely preclinical, with limited human evidence directly relevant to musculoskeletal applications24

  • expert opinionPreclinical studies on therapeutic peptides including TB-500 are promising but there is a current lack of clinical trials27

  • theoreticalNo human clinical trial has ever tested the fragment that people actually inject29

  • theoreticalNo published clinical data for any route of TB-500 administration29

How it works

Based on 1 human study finding, 22 animal findings, 33 in vitro findings, 49 expert opinion findings and 13 theoretical findings.

  • human studyThymosin beta-4 (TB4) is an X-linked gene product with cardioprotective properties2

  • animalTB-500 retains the G-actin sequestration activity of full-length Thymosin Beta-4 and produces equivalent cell migration and anti-inflammatory effects in preclinical models1

  • animalTB4 can preserve ejection fraction in animal studies of cardiac injury2

  • animalThymosin beta-4 has been shown to promote angiogenesis in several in vivo models and upregulates vascular endothelial growth factor (VEGF) expression and promotes endothelial cell migration and tube formation4

  • animalIn cardiac ischemia models, proangiogenic effects have been associated with neovascularization of damaged tissue4

  • animalThymosin beta-4 may reduce inflammation through downregulation of pro-inflammatory cytokines and chemokines4

  • animalIn corneal injury models, it has been observed to decrease levels of inflammatory mediators including interleukin-1β and tumor necrosis factor-α4

  • animalThe sulfoxide form of thymosin beta-4 (Tβ4-SO) has been specifically implicated in anti-inflammatory signaling4

Show the remaining 110

  • animalThymosin beta-4 may influence tissue repair through modulation of matrix metalloproteinases (MMPs) and promotion of extracellular matrix deposition4

  • animalStudies in dermal wound models have reported increased collagen deposition and organized matrix remodeling in treated tissues4

  • animalTB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models5

  • animalTB500 neuroprotective effects are linked to modulation of apoptosis and synaptic plasticity through regulation of genes including forkhead box B2 (Foxb2) and olfactory receptor, family 2, subfamily K, member 2 (Or2k2)6

  • animalTB4 is expressed in the developing heart9

  • animalTB4 promotes cardiac cell migration and survival9

  • animalIntravenous injections of TB4 alter the morphology of the adult epicardium9

  • animalTB4 changes resemble the characteristics of the embryo9

  • animalTB4 results in increased number of cardiac vessels9

  • animalTB4 alters the gene expression profile typical of the embryonic state9

  • animalTB4 is capable of epicardial progenitor activation9

  • animalTB4 epicardial progenitor activation effect is independent of hypoxic injury9

  • animalTb4-overexpressing transgenic mice showed higher levels of ILK, pGSK3b, and Hh activity compared with wild-type mice12

  • animalTB-500 displays pro-angiogenic properties via several complementary pathways, promoting endothelial cell migration, capillary tubule formation, and stabilization of new vascular networks16

  • animalThe LKKTET sequence is recognized as critical to angiogenic activity and mutations in this sequence greatly diminish the angiogenesis-supporting effects of Tβ416

  • in vitroThe primary known intracellular function is the sequestration of G-actin (monomeric actin), which plays a central role in cell motility and cytoskeletal organization4

  • in vitroThe active binding domain has been identified as the sequence LKKTETQ (residues 17-23)4

  • in vitroTB500 modulated expression of apoptosis-related genes in Aβ25-35-treated HT22 cells and primary cortical neurons6

  • in vitroTB500 exhibited anti-inflammatory effects by suppressing lipopolysaccharide (LPS)-induced nitric oxide (NO) production in BV2 microglia6

  • in vitroTB500 reduced expression of pro-inflammatory cytokines in BV2 microglia assays6

  • in vitroTB500 inhibited M1 microglial polarization in BV2 microglia assays6

  • in vitroNap-YpYY-TB500 hydrogel enhanced myofibroblastic differentiation and cytoskeletal reorganization of human corneal stromal fibroblasts (HCSFs) in vitro7

  • in vitroAmong three candidate sequences, Nap-YpYY-TB500 exhibited optimal gelation kinetics, nanostructure, and therapeutic efficacy7

  • in vitroTB-500 (Thymosin beta-4) is a 43 amino acid peptide with regenerative properties in various organ systems8

  • in vitroTB-500 affects the behavior of epidermal and epithelial cells of the tympanic membrane in vitro8

  • in vitroLocal epidermal progenitor cells are the primary targets of TB-500, rather than differentiated cells8

  • in vitroTB4 influences HSC activation through hedgehog (Hh) pathway12

  • in vitroHSC functions declined in TB4 siRNA-treated LX-2 cells12

  • in vitroTB4 suppression down-regulated integrin linked kinase (ILK) and phosphorylated glycogen synthase kinase 3 beta (pGSK-3B)12

  • in vitroTB4 suppression decreased expression of smoothened and GLI212

  • in vitroTB4 CRISPR blocked the activation of primary HSCs12

  • in vitroTB4 interacted with smoothened at the cytoplasm or GLI2 at the nucleus in LX-212

  • in vitroSmoothened suppression in primary HSCs decreased TB4 expression12

  • in vitroThymosin-beta-4 (TB4) is an actin-sequestering peptide that has been detected outside of cells in blood plasma or in wound fluid13

  • in vitroTB4 peptides increase cell survival rate13

  • in vitroTB4 peptides decrease caspase-3 activity13

  • in vitrosiRNA of TB4 inhibited cell viability and augmented caspase-3 activity13

  • in vitroSignificant changes in Bcl-2 phosphorylation were detected by TB4 peptide treatment13

  • in vitroTB4 peptide treatment reduced population in G2/M phase, correlated with decreased expression of cyclin B113

  • in vitroThymosin-beta-4 (TB4) has been known as actin-sequestering protein and functions in tumor metastasis14

  • in vitroTB4-HeLa cells showed a higher growth rate and a lower percentage of basal apoptosis than HeLa cells14

  • in vitroTB4-HeLa cells were more resistant to paclitaxel-induced cell death than HeLa cells14

  • in vitroTB4 transcript expression with paclitaxel treatment was dose-dependently increased in HeLa cells but that was not in TB4-HeLa cells14

  • in vitroSmall interfering RNA (siRNA) of TB4 inhibited HeLa cell growth and enhanced paclitaxel-induced cell death14

  • in vitroBasal ERK phosphorylation was elevated and basal p38 kinase phosphorylation was reduced in paclitaxel non-treated TB4-HeLa cells14

  • in vitroPaclitaxel-resistance of TB4-HeLa cells was overcome by the inhibition of basal ERK activity with PD98059 pre-treatment14

  • in vitroThe inhibition of basal p38 kinase activity with SB203580 pre-treatment attenuated the paclitaxel-induced HeLa cell death14

  • in vitroTB4 induced paclitaxel-resistance through the elevation of basal level of ERK phosphorylation14

  • expert opinionTB-500 is a synthetic peptide corresponding to amino acids 17-23 of Thymosin Beta-41

  • expert opinionThymosin Beta-4 is one of the most abundant intracellular peptides in mammalian cells1

  • expert opinionApproximately 0.5 mM concentration of Thymosin Beta-4 in platelets, the highest concentration of any non-structural protein1

  • expert opinionThymosin beta 4 (TB4) is the most abundant member of the beta-thymosin family in humans11

  • expert opinionThe main physiological role of TB4 is the regulation of actin polymerization11

  • expert opinionTB4 is involved in angiogenesis, cell survival, cell migration and fetal development11

  • expert opinionTB-500 is a synthetic N-terminal-acetylated 17-amino acid fragment of thymosin beta-4 with sequence Ac-LKKTETQ-OH, covering the actin-binding domain15

  • expert opinionThe actin-binding motif at residues 17–23 (LKKTETQ) was identified as the functional core on which TB-500 was designed15

  • expert opinionThymosin beta-4 is a 43-amino acid protein found throughout human tissue15

  • expert opinionThymosin beta-4 was originally isolated from thymic tissue and operates as an actin-sequestering protein involved in dermal wound healing, corneal repair, and post-ischemic cardiac signaling15

  • expert opinionTB-500 is a synthetic heptapeptide (Ac-LKKTETQ) that corresponds to amino acids 17–23 of thymosin beta-4 (Tβ4), a naturally occurring 43–amino acid peptide involved in actin binding, cell migration, angiogenesis, and tissue repair16

  • expert opinionTβ4 regulates cytoskeletal organization by sequestering G-actin, which influences cellular mobility and structural remodeling during wound healing and tissue regeneration16

  • expert opinionTB-500 is a lab-produced peptide that mimics the action of thymosin beta-418

  • expert opinionThymosin beta-4 is a growth hormone that helps tissues like tendons and muscles grow stronger18

  • expert opinionTB-500 fragment is derived from the actin-binding region of thymosin β-419

  • expert opinionTB-500 is a 17-residue peptide corresponding to the central actin-interacting portion of the parent protein19

  • expert opinionTB-500 (Thymosin Beta-4 acetate) is a synthetic 43-amino acid peptide derived from the naturally occurring thymosin beta-4 protein20

  • expert opinionThymosin beta-4 plays crucial roles in cellular migration, angiogenesis, and tissue regeneration20

  • expert opinionTB-500 is distinguished from endogenous thymosin beta-4 by its N-terminal acetylation, which enhances stability and biological activity20

  • expert opinionTB-500 exhibits unique properties in promoting angiogenesis, cellular migration, and tissue remodeling through its primary mechanism of actin regulation20

  • expert opinionTB-500 demonstrates remarkable resistance to proteolytic degradation and maintains activity across various physiological pH ranges20

  • expert opinionTB-500's primary mechanism involves binding to G-actin monomers, leading to prevention of actin polymerization into F-actin filaments enabling enhanced cellular motility20

  • expert opinionTB-500 promotes new blood vessel formation through upregulation of vascular endothelial growth factor (VEGF) expression and signaling20

  • expert opinionTB-500 demonstrates significant anti-inflammatory properties via reduction of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-620

  • expert opinionTB-500 promotes suppression of nuclear factor-kappa B (NF-κB) activation reducing inflammatory cascade20

  • expert opinionTB-500 influences cellular growth and repair through activation of Akt/PI3K survival pathways promoting cell survival and proliferation20

  • expert opinionTB-500 enhances ERK1/2 and p38 MAPK signaling supporting cellular repair mechanisms20

  • expert opinionTB-500 upregulates hepatocyte growth factor (HGF) expression promoting tissue regeneration20

  • expert opinionTB-500 promotes angiogenesis, cellular migration, and collagen production21

  • expert opinionTB-500 binds to actin, a protein important for cellular structure and movement21

  • expert opinionTB-500 prevents actin polymerization, allowing cells to migrate more freely to injury sites21

  • expert opinionTB-500 stimulates endothelial cell proliferation, creating new blood vessels21

  • expert opinionTB-500 is closely related to thymosin beta-4 (Tβ4), a naturally occurring protein found in nearly every human cell and in high concentration in platelets and wound fluid22

  • expert opinionTB-500 is typically a short synthetic fragment, an acetylated sequence (Ac-LKKTETQ) corresponding to residues 17–23 of thymosin beta-4, with a molecular weight of about 889 daltons22

  • expert opinionThat fragment is the actin-binding active site of the parent molecule22

  • expert opinionThe full-length protein contains additional functional regions the fragment lacks, most notably the N-terminal Ac-SDKP motif (a separately active tetrapeptide with anti-fibrotic and anti-inflammatory properties)22

  • expert opinionTB-500 retains actin-binding activity but does not carry those other domains22

  • expert opinionTB-500 is an actin-sequestering protein — meaning it binds and regulates actin, the structural protein cells use to move, migrate, and remodel tissue22

  • expert opinionTB-500 is a synthetic 7-amino-acid fragment of thymosin beta-423

  • expert opinionTB-500 sequence is Ac-LKKTETQ, which matches amino acids 17-23 of thymosin beta-423

  • expert opinionTB-500 fragment keeps the actin-binding region but does not include the rest of the parent peptide23

  • expert opinionTB-500 is a synthetic peptide derived from thymosin beta-4 that promotes tissue repair through actin regulation, enhanced cell migration, anti-inflammatory signaling, and angiogenesis25

  • expert opinionThymosin beta-4 (Tb4) is a 43-amino-acid peptide found in virtually every human cell25

  • expert opinionTB-500 is centered around the actin-binding domain, specifically the sequence Leu-Lys-Lys-Thr-Glu-Thr (LKKTET at positions 17-22)25

  • expert opinionTB-500 likely carries the same biological activity for tissue repair as the parent molecule, but this has not been rigorously validated across all applications25

  • expert opinionTb4 binds to G-actin in a 1:1 complex, preventing premature polymerization and maintaining a pool of available monomers25

  • expert opinionTB-500 is a wound-healing peptide that promotes angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation27

  • expert opinionTB-500 acts by modulating molecular signaling networks including PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK pathways27

  • expert opinionThymosin beta-4 (TB4) is an endogenous peptide with protective and regenerative effects in models of cellular and organ injury28

  • theoreticalTB-500 is the commercially available synthetic form of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide encoded by the TMSB4X gene on the X chromosome3

  • theoreticalTβ4 is ubiquitously expressed in nearly all tissues except erythrocytes, with highest concentrations in platelets and wound fluid3

  • theoreticalPrimary intracellular role is sequestering monomeric G-actin to regulate cytoskeletal dynamics, cell migration, and division3

  • theoreticalTB-500 is a synthetic peptide product that corresponds to a fragment or region of thymosin beta-4, a 43-amino acid protein that is one of the most abundant intracellular peptides in mammalian cells4

  • theoreticalTB-500 is the active synthetic fragment of thymosin beta-4 (Tβ4), a 43-amino acid protein naturally present in virtually all human cells17

  • theoreticalSequesters G-actin via thymosin β4 domain17

  • theoreticalPromotes endothelial cell migration and angiogenesis17

  • theoreticalDownregulates inflammatory cytokines (TNF-α, IL-1β)17

  • theoreticalStimulates Wnt/β-catenin pathway17

  • theoreticalTB-500 is a synthetic heptapeptide corresponding to residues 17–23 of thymosin beta-429

  • theoreticalThe fragment encompasses the actin-binding domain that researchers have identified as the active region responsible for cell migration and wound healing signaling29

  • theoreticalThymosin-β4 (TB4) is a cellular protein with known extracellular function identified as a hypothetical candidate molecule to examine as a potential mediator in mouse models of osteomyelofibrosis30

  • theoreticalTB4 has a positive effect on osteoblast formation and function30

Dosing

Based on 9 expert opinion findings and 13 anecdotal findings.

  • expert opinionInformation regarding the indications, dosing, frequency, and duration of treatment remains unknown for TB-5005

  • expert opinionSubcutaneous injection is the most common delivery route for TB-50019

  • expert opinionTypical protocols involve several injections per week during loading phases, reduced to less frequent dosing during maintenance19

  • expert opinionTypical dose of TB-500 is 2-5mg subcutaneous, twice weekly21

  • expert opinionTB-500 is most commonly dosed at 2–2.5 mg by subcutaneous injection twice per week during a 4–6 week loading phase, then reduced to roughly 2–2.5 mg once every 1–2 weeks for maintenance22

  • expert opinionSome higher-intensity protocols run 5–7.66 mg per week split across 2–3 injections during loading22

  • expert opinionA 10 mg vial mixed with 2 mL bacteriostatic water gives 5 mg/mL23

  • expert opinionAt 5 mg/mL concentration, 2-2.5 mg is 0.4-0.5 mL per dose, or roughly 40-50 units on a U-100 insulin syringe23

Show the remaining 14

  • expert opinionTwice weekly dosing produces about 4-5 mg per week during loading phase23

  • anecdotalTypical dose 2.5–5 mg twice weekly17

  • anecdotal4–8 week cycles17

  • anecdotalLoading Phase (Week 1–4): 5 mg twice weekly subcutaneous injection17

  • anecdotalMaintenance Phase (Week 5+): 2.5 mg once weekly subcutaneous injection17

  • anecdotalAcute Injury Protocol: 5 mg twice weekly x 4 weeks subcutaneous injection17

  • anecdotalPeople who buy TB-500 online typically take it as a powder, pill, or spray, meaning systemic rather than topical use18

  • anecdotalMost research-use protocols use subcutaneous injection23

  • anecdotalCommunity protocols typically use a loading phase (twice weekly) followed by a maintenance phase (once weekly)23

  • anecdotalCommon research-use cycles are 4-12 weeks23

  • anecdotalCommunity research-use plan is approximately 2-2.5 mg subcutaneous twice weekly during loading phase23

  • anecdotalMaintenance phase drops to approximately 2-2.5 mg subcutaneous once weekly23

  • anecdotalSome plans extend maintenance for 6-8 additional weeks; others stop after the loading phase23

  • anecdotalCommunity cycle planning includes 4-8 week off period after maintenance23

How the body handles it

Based on 1 human trial finding, 4 animal findings, 15 expert opinion findings and 2 theoretical findings.

  • human trialIntravenous administration provides 100% bioavailability and was used in the Phase I trial by Ruff et al. (2010) to establish reference pharmacokinetic parameters4

  • animalThymosin beta-4 is readily absorbed following subcutaneous (SC) and intramuscular (IM) injection4

  • animalPeak plasma concentrations (Tmax) typically reached within 1 to 3 hours in animal models4

  • animalBioavailability following SC injection has been estimated at approximately 70-80% based on preclinical pharmacokinetic studies4

  • animalIM injection shows comparable absorption kinetics with slightly faster Tmax due to the greater vascularity of muscle tissue4

  • expert opinionStore reconstituted solution refrigerated (2–8°C) and use within 28 days17

  • expert opinionMolecular weight is approximately 1.9 kDa19

  • expert opinionHalf-life profile of TB-500 in circulation is relatively short, consistent with the kinetics of short-chain synthetic peptides19

Show the remaining 14

  • expert opinionPlasma half-life is measured in hours; exact published values vary19

  • expert opinionTissue effects may outlast circulating levels19

  • expert opinionSublingual and oral formulations exist from some compounding partners but have reduced bioavailability relative to injection19

  • expert opinionTB-500 is typically provided as a lyophilized powder for reconstitution with bacteriostatic water19

  • expert opinionThe peptide exhibits high systemic bioavailability via subcutaneous injection and distributes widely to tissues with high metabolic activity and injury sites20

  • expert opinionThymosin Alpha-1 has a half-life of approximately 2-3 hours when administered subcutaneously21

  • expert opinionPeak plasma concentrations reached within 30-60 minutes for Thymosin Alpha-121

  • expert opinionThymosin Alpha-1 demonstrates excellent bioavailability through subcutaneous injection, with minimal hepatic metabolism21

  • expert opinionTB-500 has a longer half-life than Thymosin Alpha-1, remaining active for 7-10 days after injection21

  • expert opinionTB-500 shows high bioavailability through subcutaneous administration and distributes widely throughout body tissues21

  • expert opinionTB-500 has long tissue persistence (basis for twice-weekly dosing)22

  • expert opinionTB4 release following ex vivo platelet activation can confound clinical measurements28

  • theoreticalAcetylation modification can slow breakdown23

  • theoreticalTB-500 is NOT identical to full-length Tβ4 — different molecular weight, different structure, different pharmacokinetics, different evidence base29

Safety and side effects

Based on 2 human trial findings, 25 expert opinion findings, 4 anecdotal findings and 1 theoretical finding.

  • human trialTwo Phase 1 IV safety/pharmacokinetic studies conducted with 84 healthy volunteers total3

  • human trialPhase 1 study of full-length thymosin beta-4 in healthy volunteers received IV doses ranging from 42 mg to 1260 mg, followed by daily dosing for 14 days, with no dose-limiting toxicities23

  • expert opinionTB-500 sold by peptide vendors is a synthetic version but from unregulated sources with variable purity, distinct from pharma-grade products used in trials3

  • expert opinionTB-500 has not received FDA approval4

  • expert opinionTB-500 is prohibited under WADA S0 (unapproved substances)4

  • expert opinionSignificant research regarding the safety and efficacy of TB-500 is required before definitive recommendations can be made to patients5

  • expert opinionFollowing the February 2026 FDA reclassification, TB-500 is a 503A Category 2 bulk drug substance prohibited in compounding15

  • expert opinionTB-500 is banned at all times on the 2026 WADA Prohibited List under Section S215

Show the remaining 24

  • expert opinionTB-500 cannot be legally obtained through any licensed US pharmacy15

  • expert opinionTB-500 is not FDA-approved for human use15

  • expert opinionAs of the February 2026 reclassification, TB-500 is classified as an FDA 503A Category 2 bulk drug substance, prohibited in compounding15

  • expert opinionTB-500 is not an FDA-approved drug and is not a lawful dietary supplement ingredient16

  • expert opinionTB-500 has not received FDA approval for any indication, and regulatory agencies have not established its safety or efficacy based on available data16

  • expert opinionGenerally well-tolerated in research settings17

  • expert opinionTo be considered safe and effective for humans, studies have to go past Phase 3 FDA approval18

  • expert opinionReported safety profile of TB-500 is generally favorable19

  • expert opinionTB-500 common side effects include mild fatigue and injection site irritation21

  • expert opinionTB-500 was removed from 503A Category 2 in April 202622

  • expert opinionFDA proposed NOT to add TB-500 to the 503A bulks list at the July 23, 2026 PCAC review22

  • expert opinionTB-500 is prohibited at all times by WADA (Section S2, growth factors)22

  • expert opinionTB-500 not FDA-approved and removed from FDA 503A Category 2 on April 15, 202623

  • expert opinionTB-500 is on the World Anti-Doping Agency Prohibited List23

  • expert opinionThe assumption that the active fragment retains all properties of the parent molecule is reasonable but has not been rigorously validated25

  • expert opinionRigorous human safety data for unapproved peptides like TB-500 are scarce26

  • expert opinionThere is potential for serious harm to patients from unapproved peptides including TB-50026

  • expert opinionResidual platelets remaining in suspension after centrifugation can confound TB4 clinical measurements28

  • expert opinionThe parent protein is overexpressed in several human cancers, and the same pro-angiogenic mechanism that makes it interesting for wound healing is the mechanism that raises oncological concerns29

  • anecdotalMild nausea with higher doses17

  • anecdotalInjection site redness or discomfort17

  • anecdotalRare: Dizziness or lightheadedness17

  • anecdotalPotential effect on blood pressure (monitor if hypertensive)17

  • theoreticalTB-500 is not approved for any indication29

What people use it for

Based on 2 animal findings, 1 in vitro finding, 16 expert opinion findings, 2 anecdotal findings and 3 theoretical findings.

  • animalTB4 administration during gestation may act as a powerful fetal growth promoter by accelerating development of newborn organs and tissues11

  • animalTb4-overexpressing transgenic mice treated with CCl4 were susceptible to hepatic fibrosis development12

  • in vitroTB-500 promotes tympanic cell migration and proliferation8

  • expert opinionTB-500 has orphan drug designation for epidermolysis bullosa4

  • expert opinionTB-4 and TB-500 remain banned substances in sports5

  • expert opinionTB-500 appears on the World Anti-Doping Agency (WADA) Prohibited List16

  • expert opinionTB-500 was initially designed for veterinary purposes and was used with racehorses and was banned18

  • expert opinionTB-500 is frequently combined with BPC-157 in tissue-repair protocols19

Show the remaining 16

  • expert opinionThymosin Alpha-1 focuses on immune system enhancement while TB-500 targets tissue repair and healing21

  • expert opinionTB-500 is a synthetic peptide marketed for tissue repair and recovery22

  • expert opinionPCAC review scheduled for July 23, 2026 for potential 503A inclusion for wound healing23

  • expert opinionTB4 and TB-500 are widely discussed in tissue healing and musculoskeletal medicine24

  • expert opinionThe most common tissue categories studied were wound/skin/soft tissue, vascular/endothelial, ocular/cornea, and bone24

  • expert opinionDirect musculoskeletal tissue categories such as tendon, ligament, muscle, cartilage, and spine/intervertebral disc were comparatively sparse in the literature24

  • expert opinionTB-500 is most effective for chronic tendinopathies, post-surgical adhesions, and injuries with poor tissue remodeling25

  • expert opinionTB-500 is often combined with BPC-157 for complementary mechanisms25

  • expert opinionTB-500 (thymosin beta-4 fragment) is an unapproved peptide marketed direct to patients26

  • expert opinionTB-500 is used in sports medicine for accelerated injury recovery and performance enhancement26

  • expert opinionTB4 is increasingly measured as a potential plasma or serum biomarker in human cardiovascular, liver, infectious, and autoimmune disease28

  • anecdotalSystemic musculoskeletal use relies on animal studies and clinical observation25

  • anecdotalTB-500 is one of the most widely used peptides in the self-experimentation community — and one of the least tested in humans29

  • theoreticalTB500 has not been previously explored for corneal disease treatment7

  • theoreticalTB-500 could in theory help tissues repair better after injury18

  • theoreticalZero clinical programs use the TB-500 fragment29

Other findings

Based on 1 in vitro finding and 10 expert opinion findings.

  • in vitroTB500 has the amino acid sequence LKKTETQ7

  • expert opinionThymosin beta-4 was first isolated from the thymus gland in the 1960s as part of research on thymic hormones, though it was subsequently found to be expressed in nearly all nucleated cell types4

  • expert opinionTB-500 is banned from 503A compounding pharmacies. Only available through 503B outsourcing facilities or for research use17

  • expert opinionNot FDA-approved17

  • expert opinionFull-length thymosin beta-4 is a 43-amino-acid peptide with a molecular weight of roughly 4,963 daltons22

  • expert opinionDetection window for TB-500 in athletes is ~30–45 days22

  • expert opinionThe evidence base for TB4 and TB-500 was weighted toward mixed and in vitro designs24

  • expert opinionMost studies evaluated TB4 rather than TB-50024

Show the remaining 3

  • expert opinionSubstantial intra- and inter-study variability in healthy controls exists28

  • expert opinionLack of protocol standardization in TB4 measurement28

  • expert opinionAssay specificity towards posttranslational modifications can confound TB4 measurements28

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Contested

Whether the injected TB-500 fragment itself works is directly disputed.

Vendor/practitioner sources assume the fragment retains the parent protein's activity (TB-500 and Thymosin Beta-4 Clinical Evidence: What the Human Trial Data Shows | Research Guide | Blackwell BioLabs preclinical, TB-500 (Thymosin Beta-4): A Physician's Complete Guide — Julian Douwes M.D., TB-500 Peptide | Healing & Flexibility), but TB-500 - Status, Risks, and Bans in Sport and Military | Blog reports a March 2024 study finding that TB-500 (Ac-LKKTETQ) did NOT enhance wound healing whereas its metabolite Ac-LKKTE did. TB-500 (Thymosin Beta-4): A Physician's Complete Guide — Julian Douwes M.D. and TB-500 Dosage Guide: Complete Protocol for Safe Administration - Beverly Hills Rejuvenation Center explicitly note the assumption of retained activity has not been rigorously validated.

Limited evidence

Nearly all human clinical evidence used full-length thymosin beta-4, not the TB-500 fragment.

Multiple sources (TB-500: Research Evidence & Safety Profile | PeptideInsight, TB-500: Research, Evidence, Dosing & Safety | Peptidings, TB-500 Dosage Guide: Complete Protocol for Safe Administration - Beverly Hills Rejuvenation Center, TB-500 Dosing Guide: Protocol, Reconstitution & Safety (2026), Superpower, TB-500 for Injury Recovery – Does it Work and is it Safe?, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.) emphasize that human trials (Ruff et al. 2010 Phase 1, RGN-259 ophthalmic, SEER neurotrophic keratopathy, MOTIF cardiac, dermal wound-healing) all used pharmaceutical-grade full-length recombinant Tβ4, and that there are no completed human efficacy trials of TB-500 specifically. Thymosin Beta-4 and TB-500 in Tissue Healing ... found direct TB-500 human evidence limited to a single study.

Contested

Wound-healing benefit in humans was not conclusively superior to control.

TB-500 - Status, Risks, and Bans in Sport and Military | Blog reports the European venous stasis ulcer study (n=73) showed ~25% complete healing with 0.03% topical TB-500 and ~1 month acceleration in some patients, but states overall healing rates were not conclusively superior to control — a qualifier that vendor sources describing robust wound-healing efficacy omit.

Other

The same pro-angiogenic mechanism raises oncological safety concerns.

TB-500: Research, Evidence, Dosing & Safety | Peptidings warns the parent protein is overexpressed in several human cancers and that its pro-angiogenic mechanism raises oncological concerns. In vitro studies (Actin-sequestering protein, thymosin-beta-4 (TB4), inhibits caspase-3 activation in paclitaxel-induced tumor cell death., ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance.) report TB4 induces tumor metastasis and paclitaxel resistance, increases cancer cell survival, and decreases apoptosis. Thymosin beta-4 regulates activation of hepatic stellate cells via hedgehog signaling. reports TB4 promotes hepatic fibrosis in transgenic mice. These contrast with predominantly favorable tolerability reports (TB-500 Half-Life, Sequence, and Dosing: A Physician’s…, Thymosin Alpha-1 vs TB-500: Immune vs Healing | FormBlends, TB-500 (Thymosin Beta-4 Fragment) — Dosing, Side Effects, FDA Status & Research | PeptIQ | PeptIQ).

Limited evidence

No controlled human trial has established TB-500 dosing; protocols come from animal data and community practice.

TB-500 Dosage Guide: Complete Protocol for Safe Administration - Beverly Hills Rejuvenation Center, TB-500 Dosing Guide: Protocol, Reconstitution & Safety (2026), TB-500 (Thymosin Beta-4 Fragment) — Dosing, Side Effects, FDA Status & Research | PeptIQ | PeptIQ and Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. state dosing ranges (commonly 2–2.5 mg or 2.5–5 mg SC twice weekly during loading) are drawn from animal research and community/anecdotal practice, not validated human prescriptions, and Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. states indications, dosing, frequency and duration remain unknown.

Single source

Some mechanistic and biomarker findings rest on a single study each.

The HFpEF plasma biomarker findings (Thymosin Beta-4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction.), the fetal growth-promoter effect in mice (Thymosin beta-4 prenatal administration improves fetal development and halts side effects due to preterm delivery.), the tympanic membrane in vitro work (Thymosin beta-4 - A potential tool in healing middle ear lesions in adult mammals.), the 5×FAD Alzheimer's model results (Thymosin β4-derived peptides alleviate neuroinflammation and neurite atrophy in both in vitro models and in vivo 5 × FAD mice: A potential therapy for memory improvement in Alzheimer's disease.), and the corneal hydrogel study (Alkaline Phosphatase-Triggered Spatiotemporal Repair of Corneal Injury with TB500 Peptide Hydrogel.) each derive from a single study and have not been independently corroborated within the provided sources.

Limited evidence

Plasma TB4 biomarker measurement is confounded and unstandardized.

Sources of variability in quantifying circulating thymosin beta-4: literature review and recommendations. cautions that TB4 as a clinical biomarker suffers from substantial intra- and inter-study variability in healthy controls, lack of protocol standardization, and confounding from residual platelets, ex vivo platelet activation, and assay specificity toward posttranslational modifications.

Using it with other compounds

Check a stack
  • BPC-157Complementary

    May be complementary

    BPC-157 and TB-500 drive tissue repair through entirely different molecular targets (VEGF/NO signalling vs. actin regulation), so they are frequently discussed as a complementary healing pair rather than a redundant one.

    Tier 3Largely anecdotal — commonly discussed

    Shares tissue repair · angiogenesis

  • GHK-CuComplementary

    May be complementary

    GHK-Cu stimulates collagen/GAG synthesis and ECM remodeling while TB-500 (Thymosin β4 fragment) sequesters G-actin to promote cell migration, angiogenesis and inflammation resolution. Different mechanisms both converge on angiogenesis, integrin/ECM remodeling and NF-κB suppression — a classic complementary regeneration pairing.

    Tier 3Largely anecdotal — commonly discussed
  • KPVComplementary

    No documented conflict

    KPV dampens the inflammatory cytokine signal (TNF-α, IL-6, NF-κB), while TB-500 drives the structural side of repair through actin/cytoskeletal dynamics, angiogenesis and cell migration. One quiets inflammation, the other rebuilds tissue — a complementary pairing for wound and mucosal healing.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish the three claimed shared dimensions: (1) inflammation_resolution and anti_inflammatory effects are documented for both (KPV suppresses TNF-α, IL-1β, IL-6, COX-2; TB-500 reduces TNF-α, IL-1β, IL-6); (2) NF-κB modulation is explicitly present in both (KPV via IκBα stabilization and p65RelA nuclear import inhibition; TB-500 via NF-κB suppression). The complementary relationship is well-justified: KPV's mechanism targets inflammatory signaling pathways (NF-κB, MAPK, pyroptosis), while TB-500's mechanism addresses tissue reconstruction through G-actin sequestration, integrin-mediated ECM remodeling, angiogenesis (VEGF), and survival pathways (PI3K/Akt). The explanation accurately reflects that one peptide dampens inflammatory signals while the other drives structural repair—a genuine complementary pairing supported by their distinct but non-overlapping mechanistic profiles.

    Shares inflammation resolution · anti inflammatory · NF kB modulation

  • HexarelinComplementary

    Worth caution

    Both show cardiac-repair and anti-inflammatory signals through different routes: hexarelin via CD36/PI3K-Akt cardioprotection and NLRP3/NF-κB suppression, TB-500 via actin/cytoskeletal remodeling, angiogenesis and NF-κB suppression. They target the same repair and inflammation-resolution goals through non-overlapping mechanisms, making them a plausible complementary pair for tissue recovery.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanisms clearly establish the three shared dimensions: (1) anti_inflammatory: Hexarelin suppresses NLRP3/NF-κB and TGF-β; TB-500 reduces TNF-α/IL-1β/IL-6 and suppresses NF-κB. (2) NF_kB_modulation: Both explicitly target NF-κB suppression via different pathways (NLRP3 inflammasome for Hexarelin, direct anti-inflammatory for TB-500). (3) mTOR_PI3K: Both activate PI3K/Akt signaling (Hexarelin via GHS-R1a/PLC cascade; TB-500 via integrin/survival pathway), and both are tagged with mTOR_PI3K. The explanation correctly identifies non-overlapping mechanisms (CD36/NLRP3 vs. actin/integrin/angiogenesis) converging on shared endpoints (cardiac repair, inflammation resolution, tissue recovery). The complementary relationship is justified by the mechanism material.

    Shares anti inflammatory · NF kB modulation · mTOR PI3K

  • LL-37Complementary

    May be complementary

    Both promote wound healing, new blood-vessel growth (VEGF), and reduced inflammation, but through distinct mechanisms — LL-37 drives keratinocyte migration and angiogenesis via EGFR/FPR2, while TB-500 regulates actin/cytoskeletal dynamics and cell migration. This makes them a strong complementary tissue-repair pairing.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish the four shared dimensions claimed. LL-37 explicitly targets EGFR, FPR2, and TLR pathways leading to angiogenesis, wound healing, and keratinocyte migration with VEGF/VEGFA signaling noted. TB-500 explicitly targets integrins and G-actin for cell migration, angiogenesis via VEGF, and tissue remodeling. Both show anti-inflammatory effects (LL-37 via NF-κB/TLR signaling; TB-500 via NF-κB suppression and reduced TNF-α/IL-1β/IL-6). Both list tissue_repair, angiogenesis, anti_inflammatory, and VEGF_upregulation in approved tags. The explanation correctly identifies distinct mechanistic pathways (LL-37: EGFR/FPR2/keratinocyte-driven; TB-500: actin/cytoskeletal/integrin-driven) that would complement rather than duplicate each other. The relationship type 'complementary' is well-justified by the mechanism material.

    Shares tissue repair · angiogenesis · anti inflammatory · VEGF upregulation

  • ImunofanComplementary

    No documented conflict

    TB-500 drives cytoskeletal-based cell migration, angiogenesis and NF-κB-suppressing anti-inflammatory repair. This converges with imunofan's reported fibroblast/keratinocyte stimulation and anti-inflammatory cytokine modulation through an entirely different mechanism, supporting a complementary tissue-recovery goal.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support the claimed shared dimensions. For tissue_repair: Imunofan explicitly stimulates fibroblast and keratinocyte proliferation and tissue repair; TB-500 drives angiogenesis, cell migration, and tissue/collagen matrix remodeling—distinct but convergent mechanisms. For anti_inflammatory: Imunofan reduces TNF and IL-6 through cytokine modulation; TB-500 reduces TNF-α, IL-1β, IL-6 via NF-κB suppression—again, different pathways achieving the same outcome. The explanation accurately characterizes these as mechanistically distinct (cytokine modulation vs. NF-κB suppression; thymopoietin signaling vs. actin/integrin dynamics) yet functionally complementary for tissue recovery, which is precisely what 'complementary' should mean. The mechanisms do not contradict this relationship.

    Shares tissue repair · anti inflammatory

  • ElafinComplementary

    May be complementary

    TB-500 promotes cell migration, angiogenesis and matrix remodeling for wound healing, while elafin protects healing tissue by inhibiting neutrophil proteases and suppressing NF-κB inflammation. Distinct mechanisms both favoring tissue repair.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support the proposed complementary relationship with the three shared dimensions. Elafin inhibits neutrophil elastase, proteinase 3, and cathepsin S while modulating NF-κB and providing tissue protection at mucosal surfaces. TB-500 promotes angiogenesis, cell migration, matrix remodeling, and suppresses NF-κB/TNF-α/IL-1β/IL-6. Both are tagged with tissue_repair, anti_inflammatory, and NF_kB_modulation. The explanation accurately reflects their distinct but synergistic mechanisms: elafin acts as a protease inhibitor preventing tissue destruction during inflammation, while TB-500 actively promotes healing through cytoskeletal dynamics and angiogenesis. These represent complementary approaches to tissue repair—one protective/anti-inflammatory, one regenerative—both converging on NF-κB modulation and inflammation resolution.

    Shares tissue repair · anti inflammatory · NF kB modulation

  • MatrixylComplementary

    No documented conflict

    TB-500 supports the cell-migration and ECM-remodeling side of repair, while Matrixyl (a topical collagen matrikine) stimulates collagen I/III/IV and fibronectin production. They target different steps of matrix rebuilding \u2014 one systemic, one topical \u2014 so they complement rather than overlap.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The proposed complementary relationship is justified by the mechanism material. TB-500's mechanisms include integrin-mediated ECM remodeling, VEGF-driven angiogenesis, TGF-β signaling, and cell migration—processes that prepare tissue for and facilitate repair. Matrixyl's mechanisms focus specifically on collagen synthesis (types I, III, IV), fibronectin production, and matrix deposition—the structural rebuilding phase. The shared dimension 'tissue_repair' is explicitly present in both peptides' approved tags. The explanation correctly identifies that they address different sequential steps: TB-500 promotes the cellular and vascular environment for repair (migration, angiogenesis, remodeling signals), while Matrixyl directly stimulates the synthesis and deposition of structural matrix components. The distinction between systemic (TB-500) and topical (Matrixyl) mechanisms is supported by their respective target profiles and delivery contexts. This represents a genuine complementary relationship where both contribute to tissue repair through non-overlapping mechanisms.

    Shares tissue repair

  • Follistatin-344Complementary

    No documented conflict

    TB-500 promotes tissue repair, angiogenesis and matrix remodeling, while Follistatin reduces muscle fibrosis and inflammatory infiltration and drives hypertrophy. Different mechanisms both favoring healthier muscle/soft-tissue recovery, so they can be viewed as complementary repair agents.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms support the proposed complementary relationship on the claimed shared dimensions. (1) Anti-inflammatory: Follistatin-344 shows 'Reduced muscle fibrosis and inflammatory infiltration' and 'Reported tissue repair / anti-inflammatory effects'; TB-500 explicitly targets 'Anti-inflammatory (reduced TNF-α, IL-1β, IL-6)' and 'NF-κB (suppression, anti-inflammatory)'. Both are tagged anti_inflammatory. (2) mTOR_PI3K: Follistatin-344 mechanisms include 'mTOR pathway (disinhibited)' and 'Akt phosphorylation (increased)' with mTOR_PI3K tag; TB-500 pathways include 'PI3K/Akt survival pathway' and 'mTOR' with mTOR_PI3K tag. The explanation correctly identifies that they operate via different primary mechanisms (Follistatin via TGF-β antagonism/myostatin blockade; TB-500 via actin sequestration and integrin signaling) but converge on shared outcomes: anti-inflammatory effects and mTOR/PI3K pathway activation. Both support muscle/tissue recovery through distinct but complementary pathways, justifying the 'complementary' relationship type.

    Shares anti inflammatory · mTOR PI3K

  • Palmitoyl Tripeptide-1Complementary

    No documented conflict

    TB-500 (thymosin β4 fragment) promotes cell migration, angiogenesis and anti-inflammatory tissue repair, while Pal-GHK drives collagen and matrix deposition. They converge on the same goal of tissue healing through distinct pathways (actin/cytoskeletal remodeling vs TGF-β collagen synthesis), so they can be viewed as complementary for repair contexts.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish the two claimed shared dimensions. (1) Anti-inflammatory: Palmitoyl Tripeptide-1 shows anti-inflammatory effects via IL-6 and TNF-α suppression (src-8, src-25); TB-500 shows anti-inflammatory effects via TNF-α, IL-1β, IL-6 reduction and NF-κB suppression. (2) Tissue_repair: Both are explicitly tagged and mechanistically described as promoting tissue repair—Pal-GHK through collagen/matrix synthesis and MMP modulation; TB-500 through cell migration, angiogenesis, and ECM remodeling. The explanation correctly identifies that they operate via distinct pathways (actin/cytoskeletal dynamics vs. TGF-β-driven collagen synthesis) while converging on tissue healing outcomes. This is a classic complementary relationship: non-overlapping mechanisms addressing the same functional goal. The proposed relationship type and shared dimensions are well-justified by the provided mechanism material.

    Shares anti inflammatory · tissue repair

Safety and side effects

Reported tolerability

Community- and practitioner-level sources describe a generally favorable tolerability profile. A tier-3 comparison source (src-12) lists common side effects as mild fatigue and injection-site irritation. A tier-2/community source (src-14), drawing on 103 community reports, describes TB-500 as generally well-tolerated in research settings with possible mild nausea at higher doses, injection-site redness or discomfort, rare dizziness or lightheadedness, and a potential effect on blood pressure (advising monitoring in hypertensive users). src-10 reports a generally favorable reported safety profile.

Human safety data (mostly full-length Tβ4)

src-10 (via src-2) reports two Phase 1 IV safety/PK studies were conducted with 84 healthy volunteers total. A protocol source (src-8) reports a Phase 1 study of full-length Tβ4 in healthy volunteers used IV doses ranging from 42 mg to 1260 mg followed by daily dosing for 14 days with no dose-limiting toxicities, and src-3 notes the Phase 3 ARISE trials provided the largest human Tβ4 safety dataset. As with efficacy, these data reflect full-length pharmaceutical Tβ4, not the TB-500 fragment (src-4, src-8).

Oncological and fibrosis concerns

Several sources raise concerns that contrast with the favorable tolerability reports:

  • A tier-4 source (src-5) warns the parent protein is overexpressed in several human cancers, and that the same pro-angiogenic mechanism of interest for wound healing raises oncological concerns.
  • Tier-2 in vitro studies report TB4 induces tumor metastasis and paclitaxel resistance, increasing cancer-cell survival and decreasing caspase-3 activity, altering Bcl-2 phosphorylation and reducing the G2/M population (src-23), and inducing paclitaxel resistance via elevated basal ERK phosphorylation (reversed by PD98059) (src-26).
  • A tier-2 study (src-24) reports TB4 promotes hepatic fibrosis in CCl4-treated transgenic mice via hedgehog-pathway activation.

Broader caveats

A tier-2 orthopaedic review (src-18) states human orthopaedic data are lacking, dosing/frequency/duration remain unknown, and that significant safety and efficacy research is required before definitive recommendations can be made. A tier-3 review (src-19) describes TB-500 as an unapproved peptide marketed direct to patients with scarce rigorous human safety data and potential for serious harm. src-11 states regulatory agencies have not established its safety or efficacy. Sources uniformly note TB-500 is not FDA-approved and is prohibited under WADA (see Overview). Reported material properties for reference: molecular weight ~4,963.5 g/mol for full-length Tβ4 (src-24/src-4/src-42) versus ~843-889 Da for the fragment (src-5, src-25, src-34).

Reconstitution and handling

Dosing

No dose has been established for this compound. Multiple sources (src-7, src-8, src-14, src-18) state that no controlled human trial has ever established a TB-500 dose, and that ranges come from animal research and community/anecdotal practice rather than a validated human prescription; src-18 states indications, dosing, frequency and duration remain unknown. No regulatory label exists, so the figures below are what sources report — not guidance.

  • A tier-3 dosing guide (src-7) describes the most common dosing as 2–2.5 mg subcutaneously twice per week during a 4–6 week loading phase, then reduced to roughly 2–2.5 mg once every 1–2 weeks for maintenance, with some higher-intensity protocols running 5–7.66 mg per week split across 2–3 injections during loading — and explicitly stresses these are drawn largely from animal research and community practice.
  • A tier-3 protocol source (src-8) describes community research-use plans of ~2–2.5 mg SC twice weekly during loading (weeks 1–6, ~4–5 mg/week), dropping to 2–2.5 mg once weekly for maintenance (weeks 7–12), with 4–8 week off periods and cycle length commonly 4–12 weeks.
  • A community source (src-14) describes 2.5–5 mg twice weekly in 4–8 week cycles: a loading phase (weeks 1–4) of 5 mg twice weekly SC, maintenance (week 5+) of 2.5 mg once weekly SC, and an acute-injury protocol of 5 mg twice weekly for 4 weeks.
  • A comparison source (src-12) cites a typical dose of 2–5 mg SC twice weekly at a reported monthly cost of $150–350; src-6 reports a 4–6 week loading phase and a cost of 100–300 EUR/month, and notes TB-500 is often combined with BPC-157 (also noted by src-10).

No human trial has tested any of these fragment protocols (src-5, src-7). src-6 describes TB-500 as most discussed for chronic tendinopathies, post-surgical adhesions, and injuries with poor tissue remodeling.

Routes

src-10 reports subcutaneous injection is the most common route (several injections weekly during loading, reduced for maintenance), that sublingual and oral formulations exist from some compounding partners but have reduced bioavailability relative to injection, and that TB-500 is typically supplied as lyophilized powder for reconstitution. src-4 reports SC and IM absorption with Tmax ~1–3 hours in animal models and SC bioavailability ~70–80%, and IV giving 100% bioavailability. A podcast (src-15) notes online buyers typically use powder, pill or spray forms.

Reconstitution arithmetic (as reported by sources)

These are calculations about a vial, not dosing guidance:

  • src-7: a 5 mg vial reconstituted in 2 mL bacteriostatic water yields 2.5 mg/mL; 0.8 mL = 80 units on a U-100 insulin syringe. Store at 2–8°C and use within ~28–30 days.
  • src-8: a 10 mg vial in 2 mL bacteriostatic water gives 5 mg/mL, so 2–2.5 mg is 0.4–0.5 mL (40–50 units on a U-100 syringe).
  • src-14: reconstituted solution should be stored refrigerated (2–8°C) and used within 28 days.

src-7 also notes long tissue persistence (the reported basis for twice-weekly dosing) and an athlete detection window of ~30–45 days; src-2/src-4 note pharma-grade RGN-259 ophthalmic solution is formulated at 0.1% (src-11 cites 0.03% topical in the venous-ulcer study).

Sources

Ordered by evidence quality — the strongest first.

  1. TB-500 and Thymosin Beta-4 Clinical Evidence: What the Human Trial Data Shows | Research Guide | Blackwell BioLabs(opens in a new tab)
    Tier 1Web · blackwellbiolabs.com · 2026
  2. Thymosin Beta-4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2017
  3. TB-500 · Compound Monograph | Apotheon(opens in a new tab)
    Tier 2Web · apotheon.io
  4. TB-500: Research Evidence & Safety Profile | PeptideInsight(opens in a new tab)
    Tier 2Web · peptideinsight.com · 2026
  5. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  6. Thymosin β4-derived peptides alleviate neuroinflammation and neurite atrophy in both in vitro models and in vivo 5 × FAD mice: A potential therapy for memory improvement in Alzheimer's disease.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  7. Alkaline Phosphatase-Triggered Spatiotemporal Repair of Corneal Injury with TB500 Peptide Hydrogel.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  8. Thymosin beta-4 - A potential tool in healing middle ear lesions in adult mammals.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  9. Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  10. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  11. Thymosin beta-4 prenatal administration improves fetal development and halts side effects due to preterm delivery.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  12. Thymosin beta-4 regulates activation of hepatic stellate cells via hedgehog signaling.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2017
  13. Actin-sequestering protein, thymosin-beta-4 (TB4), inhibits caspase-3 activation in paclitaxel-induced tumor cell death.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2007
  14. ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2006
  15. Superpower(opens in a new tab)
    Tier 3Web · superpower.com
  16. TB-500 - Status, Risks, and Bans in Sport and Military | Blog(opens in a new tab)
    Tier 3Web · bscg.org
  17. TB-500 (Thymosin Beta-4 Fragment) — Dosing, Side Effects, FDA Status & Research | PeptIQ | PeptIQ(opens in a new tab)
    Tier 3Web · peptiq.io
  18. TB-500 for Injury Recovery – Does it Work and is it Safe?(opens in a new tab)
    Tier 3Web · youtube.com
  19. TB-500 Half-Life, Sequence, and Dosing: A Physician’s…(opens in a new tab)
    Tier 3Web · newtropin.com
  20. TB-500 Peptide | Healing & Flexibility(opens in a new tab)
    Tier 3Web · paragonsportsmedicine.com
  21. Thymosin Alpha-1 vs TB-500: Immune vs Healing | FormBlends(opens in a new tab)
    Tier 3Web · formblends.com
  22. TB-500 Dosage Guide: Complete Protocol for Safe Administration - Beverly Hills Rejuvenation Center(opens in a new tab)
    Tier 3Web · bhrcenter.com · 2026
  23. TB-500 Dosing Guide: Protocol, Reconstitution & Safety (2026)(opens in a new tab)
    Tier 3Web · peptidedosingprotocols.com · 2026
  24. Thymosin Beta-4 and TB-500 in Tissue Healing ...(opens in a new tab)
    Tier 3Web · mdpi.com · 2026
  25. TB-500 (Thymosin Beta-4): A Physician's Complete Guide — Julian Douwes M.D.(opens in a new tab)
    Tier 3Web · juliandouwes.com · 2026
  26. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  27. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  28. Sources of variability in quantifying circulating thymosin beta-4: literature review and recommendations.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2018
  29. TB-500: Research, Evidence, Dosing & Safety | Peptidings(opens in a new tab)
    Tier 4Web · peptidings.com · 2026
  30. Platelets and osteoblasts: secretome connections.(opens in a new tab)
    Tier 4PubMed · pubmed.ncbi.nlm.nih.gov · 2022